FEATURED

Presence of an Artificial Intelligence–powered Predictive Biomarker Is Associated with a Poor Response to Intravesical Bacillus Calmette-Guerin but Not to Intravesical Sequential Gemcitabine/Docetaxel in High-grade Non–muscle-invasive Bladder Cancer

April 25, 2025

News & Resources

Latest News

Artificial Intelligence Biomarkers Predict Poor Efficacy of Bacillus Calmette-Guérin Rechallenge in Previously Bacillus Calmette-Guérin–Treated Nonmuscle-Invasive Bladder Cancer

Journal of Urology

July 2025

Artificial Intelligence Biomarkers Predict Poor Efficacy of Bacillus Calmette-Guérin Rechallenge in Previously Bacillus Calmette-Guérin–Treated Nonmuscle-Invasive Bladder Cancer

Journal of Urology

July 2025

Valar Labs’ CHAI Biomarkers Validated in New Study in European Urology for Predicting Outcomes of High Grade Ta Bladder Cancer

Businesswire

June 2025

Valar Labs’ CHAI Biomarkers Validated in New Study in European Urology for Predicting Outcomes of High Grade Ta Bladder Cancer

Businesswire

June 2025

Computational Histology Artificial Intelligence Enhances Risk Stratification of High-grade Ta Non–muscle-invasive Bladder Cancer in a Multicenter Cohort: Comparison to Current EAU and AUA Stratification Schemes

European Urology

June 2025

Computational Histology Artificial Intelligence Enhances Risk Stratification of High-grade Ta Non–muscle-invasive Bladder Cancer in a Multicenter Cohort: Comparison to Current EAU and AUA Stratification Schemes

European Urology

June 2025